Moolec Science (MLECW) Depreciation & Amortization (CF) (2022 - 2024)
Moolec Science (MLECW) posted Depreciation & Amortization (CF) of $52621.0 for Q4 2024, up 9.39% sequentially from $48102.0 in Q3 2024, and up 190.96% YoY from $18085.0 in Q1 2024.
Moolec Science (MLECW) Depreciation & Amortization (CF) (2022 - 2024) Analysis & Trends
Moolec Science has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $52621.0 in Q4 2024.
- Quarterly Depreciation & Amortization (CF) rose 190.96% year-over-year to $52621.0 in Q4 2024, while the trailing twelve-month figure through Mar 2026 was $52621.0 (changed N/A YoY) and the FY2025 annual result came in at $6.0 million, up 3.72% from the prior year.
- Depreciation & Amortization (CF) grew to $52621.0 in Q4 2024 per MLECW's latest filing, from $48102.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $5.8 million in Q2 2024 and troughed at -$6646.0 in Q1 2024.
- A 3-year average of $991370.2 and a median of $18085.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 9460.24% in 2023, then slumped 1663.76% in 2024.
- Over 3 years, Depreciation & Amortization (CF) stood at $424.0 in 2022, then soared by 4165.33% to $18085.0 in 2023, then jumped by 190.96% to $52621.0 in 2024.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $52621.0, $48102.0, and $5.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 52,621.00 |
| Dec 31, 2024 | 52,621.00 |
| Sep 30, 2024 | 48,102.00 |
| Sep 30, 2024 | 48,102.00 |
| Jun 30, 2024 | 5.81 Mn |
| Jun 30, 2024 | 5.81 Mn |
| Mar 31, 2024 | -6,646.00 |
| Mar 31, 2024 | -6,646.00 |
| Dec 31, 2023 | 18,085.00 |
| Dec 31, 2023 | 18,085.00 |
| Sep 30, 2023 | 40,631.00 |
| Sep 30, 2023 | 40,631.00 |
| Jun 30, 2023 | 4.94 Mn |
| Jun 30, 2023 | 4.94 Mn |
| Mar 31, 2023 | 425.00 |
| Mar 31, 2023 | 425.00 |
| Dec 31, 2022 | 424.00 |
| Dec 31, 2022 | 424.00 |
| Sep 30, 2022 | 425.00 |
| Sep 30, 2022 | 425.00 |